journal article·2026-01

Dual Fe‐Active‐Site Engineering in MCOF Nanozymes for Synergistic and Broad‐Spectrum Antibacterial Therapy

Jingqi Liu, Guimei Han, Manying Li, Xiaoyang Liu, Yan Tan, Anna Tang, Hongxin Jiang, Lina Zhu, Deming Kong

Small· Volume 22· Issue 4
Publisher page

Abstract

Abstract Nanozymes have emerged as promising broad‐spectrum antibacterial agents, with metal‐covalent organic frameworks (MCOFs) being particularly notable for their peroxidase (POD)‐like and photocatalytic oxidase (OXD)‐like activities. However, conventional MCOFs suffer from unstable metal‐loading structures and low metal content. Herein, a novel MCOF is developed, termed PA‐FeFe COF, with dual Fe active sites using a one‐pot construction involving 1,10‐phenanthroline‐5,6‐dione (PA), 4,4′,4′″‐(1,3,5‐triazine‐2,4,6‐triyl)triphenylamine (TAPT), and FeCl 3 . This design achieves high Fe‐loading, significantly enhancing both POD‐like activity through Fenton‐like reactions and photocatalytic OXD‐like activity by improving electron‐hole separation efficiency. PA‐FeFe COF demonstrates exceptional antibacterial performance, achieving over 99% inhibition rates against both Gram‐positive and Gram‐negative bacteria. The dual Fe sites display complementary electronic properties and synergistically generate reactive oxygen species (ROS), while the material's strong positive charge facilitates electrostatic adsorption onto bacterial membranes, further enhancing antibacterial efficacy. Additionally, PA‐FeFe COF exhibits self‐sustaining H 2 O 2 production and maintains its antibacterial activity after five cycles. In vivo experiments using antibiotic‐resistant bacterial infected wound models confirm the material's practical potential, showing rapid wound healing, high bacterial clearance rates, and good biocompatibility. This work not only establishes a new benchmark for metal‐loading in MCOFs but also provides fundamental insights into the rational design of multifunctional nanozymes for combating antibiotic‐resistant infections.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Covalent Organic Framework Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Research Centre for Analytical Sciences College of Chemistry Nankai University Tianjin 300071 P R China

Department of Urology Tianjin Institute of Urology The Second Hospital of Tianjin Medical University Tianjin 300211 P. R. China

Agro‐Environmental Protection Institute Ministry of Agriculture and Rural Affairs Tianjin 300191 P. R. China

Department of Chemistry School of Science Tianjin University Tianjin 300354 P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Tianjin Municipality

References (44)

Show source-provided references
1. 10.1002/adma.20230594010.1002/adma.202305940 ↗
2. 10.1016/j.watres.2024.12137310.1016/j.watres.2024.121373 ↗
3. 10.1002/adfm.20240276110.1002/adfm.202402761 ↗
4. 10.1002/adma.20140023810.1002/adma.201400238 ↗
5. 10.1038/nnano.2007.26010.1038/nnano.2007.260 ↗
6. 10.1039/c3cs35486e10.1039/c3cs35486e ↗
7. 10.1039/D5SC01014D10.1039/D5SC01014D ↗
8. 10.1021/acs.jmedchem.4c0258410.1021/acs.jmedchem.4c02584 ↗
9. 10.1021/acsnano.4c1714810.1021/acsnano.4c17148 ↗
10. 10.1002/adfm.20241891010.1002/adfm.202418910 ↗
11. 10.1038/s41467-022-33098-y10.1038/s41467-022-33098-y ↗
12. 10.1002/advs.20230868410.1002/advs.202308684 ↗
13. 10.1002/adma.20200542310.1002/adma.202005423 ↗
14. 10.1002/ange.20210771210.1002/ange.202107712 ↗
15. 10.1016/j.micres.2025.12814910.1016/j.micres.2025.128149 ↗
16. 10.1016/j.ccr.2024.21629810.1016/j.ccr.2024.216298 ↗
17. 10.1002/adma.20220568010.1002/adma.202205680 ↗
18. 10.1039/D4NR04944F10.1039/D4NR04944F ↗
19. 10.1039/C9SC05506A10.1039/C9SC05506A ↗
20. 10.1016/j.cej.2024.15226510.1016/j.cej.2024.152265 ↗
21. 10.1021/jacs.3c0516210.1021/jacs.3c05162 ↗
22. 10.1002/anie.20250574210.1002/anie.202505742 ↗
23. 10.1021/jacs.5c1650510.1021/jacs.5c16505 ↗
24. 10.1021/acs.jmedchem.3c0147910.1021/acs.jmedchem.3c01479 ↗
25. 10.1039/C3TB20832J10.1039/C3TB20832J ↗
26. 10.1002/adma.20080003010.1002/adma.200800030 ↗
27. 10.1002/adfm.20240683410.1002/adfm.202406834 ↗
28. 10.1038/nmat461110.1038/nmat4611 ↗
29. 10.1002/smll.20250251410.1002/smll.202502514 ↗
30. 10.1002/smll.20241127310.1002/smll.202411273 ↗
31. 10.1021/acs.analchem.2c0532910.1021/acs.analchem.2c05329 ↗
32. 10.1016/j.cej.2025.16263410.1016/j.cej.2025.162634 ↗
33. 10.1016/j.ccr.2021.21397010.1016/j.ccr.2021.213970 ↗
34. 10.1002/smll.20240895910.1002/smll.202408959 ↗
35. 10.1016/j.xcrp.2024.10184510.1016/j.xcrp.2024.101845 ↗
36. 10.1021/acsnano.4c1389910.1021/acsnano.4c13899 ↗
37. 10.1002/aenm.20230279710.1002/aenm.202302797 ↗
38. 10.1038/s41467-025-59541-410.1038/s41467-025-59541-4 ↗
39. 10.1021/jacs.4c0418510.1021/jacs.4c04185 ↗
40. 10.1016/j.jcis.2025.13817810.1016/j.jcis.2025.138178 ↗
41. 10.1021/acs.analchem.3c0100510.1021/acs.analchem.3c01005 ↗
42. 10.1073/pnas.232003012110.1073/pnas.2320030121 ↗
43. Ye J.‐Y. · Adv. Sci. · 2023 · 7
44. 10.1021/jacs.2c0692010.1021/jacs.2c06920 ↗